<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651336</url>
  </required_header>
  <id_info>
    <org_study_id>ARGOS-03</org_study_id>
    <secondary_id>CIV-18-13-023284</secondary_id>
    <nct_id>NCT03651336</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)</brief_title>
  <official_title>A Prospective, Open-label, Multicenter Clinical Follow-up Investigation of the ARGOS-01 and ARGOS-02 Patients to Assess the Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Implandata Ophthalmic Products GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Implandata Ophthalmic Products GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO
      system in patients with Primary Open Angle Glaucoma (POAG)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective open-label, multicenter study for clinical follow-up of the
      ARGOS-01 and ARGOS-02 patients.

      From the ARGOS-01 to the ARGOS-02 study, some modifications were made to the form of the
      ARGOS-IO implant in consequence of the outcomes of the ARGOS-01 study.

      Maximal 5 patients of the ARGOS-01 study and maximal 21 patients of the ARGOS-02 study will
      take part in this study.

      The sensor was always implanted in one eye only which will be the study eye.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by Incidence of medical-device related adverse events and serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>The primary objective of this clinical trial is to evaluate the long-term safety and tolerability of the ARGOS-IO pressure sensor under consideration of incidence, nature, severity and seriousness of observed medical device related adverse and serious adverse events.An AE is considered to be device-related if there is at least a possible relationship to the medical device according to the rating of the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limits of agreement between IOP measurements made using GAT and the ARGOS-IO system at each study visit.</measure>
    <time_frame>3 years</time_frame>
    <description>IOP measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Limits of agreement between IOP measurements made using DCT and the ARGOS-IO system at each study visit.</measure>
    <time_frame>3 Years</time_frame>
    <description>IOP measured in mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of observed device malfunctions and nature of device malfunction</measure>
    <time_frame>3 years</time_frame>
    <description>A device malfunction is e.g. difference of more than 5 mmHg between ARGOS-IO and GAT, readout error of the Mesograph because of measurements outside -2 and +70mmHG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's compliance in IOP self-monitoring</measure>
    <time_frame>3 years</time_frame>
    <description>Daily self-measurements with the ARGOS-IO sensor should be done at least 4 times daily (morning, noon, afternoon, evening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of IOP self-monitoring on glaucoma progression</measure>
    <time_frame>3 years</time_frame>
    <description>Visual field (db), cup/disc ratio, OCT of the optic nerve (µm) and the IOP (mmHg) has to be compared together to evaluate glaucoma progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence in glaucoma medication change</measure>
    <time_frame>3 years</time_frame>
    <description>Number of glaucoma medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unscheduled visits due to self-measured increased intraocular pressure</measure>
    <time_frame>3 years</time_frame>
    <description>The patients decide to come for a visit by their own due to any reason. This will be documented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Single-arm longterm follow-up ARGOS-IO Sensor Pressure System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARGOS-IO Sensor Pressure System</intervention_name>
    <description>The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02</description>
    <arm_group_label>Single-arm longterm follow-up ARGOS-IO Sensor Pressure System</arm_group_label>
    <other_name>EYEMATE-IO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of the ARGOS-01 and ARGOS-02 study with an implanted ARGOS-IO pressure
             sensor.

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagen Thieme, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsaugenklinik Magdeburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janina Hadeler</last_name>
    <phone>+49 17661944731</phone>
    <email>jhadeler@implandata.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Max Ostermeier</last_name>
    <phone>+49 51122042581</phone>
    <email>mostermeier@implandata.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für Augenheilkunde, Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonis Koutsona, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Dick, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internationale Innovative Opthalmochirurgie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hakan Kaymak, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>nordBLICK Augenklinik Bellevue</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Rüfer, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsaugenklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagen Thieme, Prof.</last_name>
      <email>hagen.thieme@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bogomil Voykov, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POAG</keyword>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>Cataract</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Intraocular Pressure Sensor System</keyword>
  <keyword>IOP</keyword>
  <keyword>Self-monitoring of intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

